The proposal would expand coverage of anti-obesity drugs to 7.5 million people covered by Medicare and Medicaid, the Biden administration said.

This may be the first Thanksgiving for millions of Americans who are on GLP-1 agonists like Ozempic, Zepbound or Wegovy.

Millions of Americans would be eligible to have costly weight-loss drugs like Wegovy or Ozempic covered by Medicare or Medicaid under the rule.

The potential health benefits of GLP-1 diabetes and weight loss meds keep piling up: New research shows they may also shield your kidneys from harm. In the largest study to date on the effects of the drugs on the kidneys, researchers found GLP-1s help the protect the organs in people with or without diabetes.

President Joe Biden’s proposal to have GLP-1 weight-loss drugs such as Ozempic and Mounjaro covered by Medicare and Medicaid would help tackle the public-health crisis of obesity, but it would raise the costs for the government programs by billions of dollars per year.

The Biden administration is proposing a rule that would require the US government to cover obesity drugs for millions of Americans, teeing up a financial and political challenge for President-elect Donald Trump as he prepares to take office.

Under a new proposal from President Biden, weight loss drugs would be covered by Medicare and Medicaid. NBC News medical contributor Dr. Natalie Azar joins José Díaz-Balart to provide insight on who would benefit from the expanded coverage and what the approval process would look like.